section name header

Pronunciation

bye-ka-LOOT-a-mide

Classifications

Therapeutic Classification: antineoplastics

Pharmacologic Classification: antiandrogens

Indications

High Alert


Action

  • Antagonizes the effects of androgen at the cellular level.
Therapeutic effects:
  • Decreased spread of prostate cancer.

Pharmacokinetics

Absorption: Well absorbed following oral administration.

Distribution: Unknown.

Protein Binding: 96%.

Metabolism/Excretion: Mostly metabolized by the liver. Excreted in the urine and feces.

Half-Life: 5.8 days.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POunknown31.3 hrunknown



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: chest pain, hypertension, peripheral edema

Derm: hot flashes, alopecia, photosensitivity, rash, sweating

Endo: breast pain, gynecomastia, hyperglycemia

GI: constipation, diarrhea, nausea, liver enzymes, abdominal pain, HEPATOTOXICITY, vomiting

GU: fertility, erectile dysfunction, hematuria, incontinence, nocturia, urinary tract infections

Hemat: anemia

Metab: weight

MS: pain

Neuro: weakness, dizziness, headache, insomnia, paresthesia

Resp: dyspnea

Misc: flu-like syndrome, infection

Interactions

Drug-drug:

Route/Dosage

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Casodex

Code

NDC Code